Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Wanbangde Pharmaceutical Holding Group Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Wanbangde Pharmaceutical Holding Group's earnings have been declining at an average annual rate of -34.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 42.3% per year. Wanbangde Pharmaceutical Holding Group's return on equity is 1%, and it has net margins of 3.6%.
Anahtar bilgiler
-34.4%
Kazanç büyüme oranı
-37.3%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 10.9% |
Gelir büyüme oranı | -42.3% |
Özkaynak getirisi | 1.0% |
Net Marj | 3.6% |
Sonraki Kazanç Güncellemesi | 30 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
Wanbangde Pharmaceutical Holding Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 1,556 | 55 | 484 | 54 |
31 Mar 24 | 1,586 | 51 | 479 | 53 |
31 Dec 23 | 1,542 | 49 | 482 | 54 |
30 Sep 23 | 1,621 | -60 | 584 | 54 |
30 Jun 23 | 1,794 | 67 | 623 | 58 |
31 Mar 23 | 1,839 | 96 | 622 | 59 |
01 Jan 23 | 1,786 | 93 | 619 | 59 |
30 Sep 22 | 1,818 | 162 | 654 | 70 |
30 Jun 22 | 1,733 | 112 | 562 | 72 |
31 Mar 22 | 1,681 | 164 | 607 | 69 |
01 Jan 22 | 1,931 | 167 | 624 | 76 |
30 Sep 21 | 3,787 | 316 | 571 | 108 |
30 Jun 21 | 7,935 | 277 | 664 | 149 |
31 Mar 21 | 11,723 | 265 | 694 | 182 |
31 Dec 20 | 13,702 | 285 | 692 | 185 |
30 Sep 20 | 15,432 | 230 | 796 | 170 |
30 Jun 20 | 15,170 | 284 | 716 | 157 |
31 Mar 20 | 15,839 | 298 | 688 | 160 |
31 Dec 19 | 16,691 | 295 | 695 | 163 |
30 Sep 19 | 3,133 | 296 | 582 | 95 |
30 Jun 19 | 2,517 | 259 | 504 | 84 |
31 Mar 19 | 1,437 | 198 | 409 | 61 |
31 Dec 18 | 736 | 162 | 313 | 46 |
30 Sep 18 | 14,804 | 89 | 220 | 69 |
30 Jun 18 | 15,203 | 103 | 174 | 60 |
31 Mar 18 | 14,637 | 100 | 139 | 36 |
31 Dec 17 | 14,635 | 98 | 119 | 22 |
30 Sep 17 | 13,112 | 74 | 71 | 25 |
30 Jun 17 | 11,360 | 61 | 82 | 0 |
31 Mar 17 | 10,114 | 68 | 87 | 0 |
31 Dec 16 | 9,183 | 70 | 88 | 0 |
30 Sep 16 | 9,262 | 49 | 92 | 0 |
30 Jun 16 | 10,485 | 53 | 97 | 0 |
31 Mar 16 | 11,349 | 62 | 98 | 0 |
31 Dec 15 | 11,572 | 63 | 94 | 0 |
30 Sep 15 | 11,227 | 101 | 104 | 0 |
30 Jun 15 | 10,833 | 101 | 118 | 0 |
31 Mar 15 | 11,003 | 97 | 127 | 0 |
31 Dec 14 | 11,452 | 108 | 130 | 0 |
30 Sep 14 | 11,747 | 115 | 136 | 0 |
30 Jun 14 | 11,498 | 115 | 121 | 0 |
31 Mar 14 | 11,434 | 117 | 114 | 0 |
31 Dec 13 | 11,786 | 112 | 113 | 0 |
Kaliteli Kazançlar: 002082 has a large one-off gain of CN¥28.0M impacting its last 12 months of financial results to 30th June, 2024.
Büyüyen Kar Marjı: 002082's current net profit margins (3.6%) are lower than last year (3.7%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 002082's earnings have declined by 34.4% per year over the past 5 years.
Büyüme Hızlandırma: 002082's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: 002082 had negative earnings growth (-17.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).
Özkaynak Getirisi
Yüksek ROE: 002082's Return on Equity (1%) is considered low.